The most common type of myositis depends on the patient’s age. In adults over 50, inclusion body myositis (IBM) is the most common acquired inflammatory muscle disease. In younger adults, dermatomyositis and polymyositis are more frequently diagnosed, and in children, juvenile dermatomyositis is the dominant form. Across all ages and subtypes, the inflammatory myopathies collectively affect about 14 per 100,000 people, with an incidence of roughly 11 new cases per million person-years.
The Major Types of Myositis
Myositis refers to a group of conditions called idiopathic inflammatory myopathies. “Idiopathic” means the exact trigger is unknown, though they all involve the immune system attacking muscle tissue. The main subtypes are dermatomyositis, polymyositis, inclusion body myositis, and immune-mediated necrotizing myopathy. Each has a distinct pattern of muscle weakness, a different typical age of onset, and a different response to treatment.
Except for inclusion body myositis, all subtypes are roughly twice as common in women as in men. IBM flips that ratio, occurring about twice as often in men.
Inclusion Body Myositis in Adults Over 50
IBM is the most common acquired muscle disease in people over 50, and because myositis in general skews toward older adults, IBM accounts for a large share of all cases. It progresses slowly, often over years, and its hallmark is a distinctive pattern of weakness that sets it apart from other forms.
Rather than causing the symmetric, proximal weakness typical of other myositis subtypes, IBM targets specific muscles asymmetrically. The quadriceps (front of the thigh) and the deep finger flexors in the forearm are hit earliest and hardest. In practical terms, that means people with IBM often notice:
- Weakening grip strength, making it harder to open jars or hold objects
- Difficulty climbing stairs or getting up from a chair
- Frequent tripping or falls because the knees buckle or the feet drop
- Slower walking speed that gradually worsens
Weakness in the distal finger flexors, tested by bending the tip of each finger against resistance, is often the earliest detectable sign. IBM also responds poorly to the immunosuppressive treatments that help other forms of myositis, which is one of the criteria doctors use to confirm the diagnosis.
Dermatomyositis: The Most Recognizable Form
Dermatomyositis is the most visually distinctive myositis because it involves the skin in addition to the muscles. Two rashes are considered hallmark signs. The heliotrope rash is a violet or reddish discoloration on the upper eyelids, sometimes with swelling around the eyes. Gottron papules are raised, reddish or purple patches over the knuckles and finger joints, sometimes with scaling or small ulcers. These skin findings can be subtle or hard to detect on darker skin tones.
The muscle weakness in dermatomyositis is typically symmetric and proximal, meaning it affects the shoulders, upper arms, hips, and thighs on both sides of the body. People often notice trouble raising their arms overhead, climbing stairs, or standing from a low seat. In children, juvenile dermatomyositis is the most common childhood inflammatory myopathy, with an incidence of about 2 to 3 cases per million children per year.
Polymyositis and Necrotizing Myopathy
Polymyositis causes symmetric proximal muscle weakness similar to dermatomyositis but without the skin involvement. It has become a somewhat controversial diagnosis in recent years because improved testing, particularly for specific antibodies, has allowed many cases once labeled as polymyositis to be reclassified as immune-mediated necrotizing myopathy (IMNM) or other subtypes.
IMNM involves rapid, severe muscle damage driven by specific antibodies. Between one-third and two-thirds of patients with IMNM carry antibodies against either a cholesterol-related enzyme (associated with statin use in some cases) or a protein involved in cell signaling. The prevalence of IMNM in people 50 and older is roughly 1.85 per 100,000, making it less common than IBM but increasingly recognized as a distinct entity.
How Myositis Is Diagnosed
Diagnosis relies on a combination of clinical features, blood tests, and sometimes a muscle biopsy. Blood tests look for elevated muscle enzymes, which indicate active muscle damage, and for specific autoantibodies that help pinpoint the subtype. The most commonly detected antibody across all myositis patients is anti-Jo-1, found in about 19% of cases in a large European study of over 1,600 patients. Other antibodies are each found in fewer than 8% of patients but can point toward specific subtypes or predict complications like lung involvement.
The international classification criteria developed jointly by European and American rheumatology organizations use a scoring system that weighs factors like age of onset, the pattern of weakness, skin rashes, lab results, and biopsy findings. A score translating to at least a 55% probability of inflammatory myopathy is considered a “probable” diagnosis, while a score corresponding to 90% or higher probability is classified as “definite.” Once the overall diagnosis is established, doctors use a decision tree to assign the specific subtype.
For IBM specifically, diagnosis requires either documented finger flexor weakness that does not improve with standard immunosuppressive treatment, or a muscle biopsy showing a characteristic finding called rimmed vacuoles, which are tiny structural abnormalities visible under a microscope.
Why the Subtype Matters
Knowing which type of myositis you have directly shapes what treatment looks like and what to expect over time. Dermatomyositis and polymyositis generally respond to immune-suppressing therapies, and many people see meaningful improvement in strength. IBM, by contrast, does not reliably respond to these same treatments, so management focuses more on physical therapy, fall prevention, and adaptive strategies to maintain function as long as possible. IMNM can cause rapid and severe weakness but often improves with aggressive immune-targeted treatment, especially when the triggering antibody is identified early.
Dermatomyositis also carries a modestly increased risk of certain cancers, so screening is part of routine follow-up. IBM’s slow progression means many people live with the disease for years before it significantly limits independence, though the quadriceps and hand weakness can eventually make walking and fine motor tasks difficult. The trajectory is highly individual, and early recognition of the correct subtype helps set realistic expectations and match the right approach to each person’s situation.